Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].
Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N. Anthony S, et al. Among authors: sebban c. Bull Cancer. 2017 Mar;104(3):221-231. doi: 10.1016/j.bulcan.2017.01.007. Epub 2017 Feb 15. Bull Cancer. 2017. PMID: 28214006 French.
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, Salles G, Henry-Amar M. Mounier N, et al. Among authors: sebban c. Cancer. 2019 Jul 1;125(13):2291-2299. doi: 10.1002/cncr.32040. Epub 2019 Mar 22. Cancer. 2019. PMID: 30901086 Free article.
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Fermé C, Copin MC, Lamy T. Morschhauser F, et al. Among authors: sebban c. Cancer. 2010 Sep 15;116(18):4299-308. doi: 10.1002/cncr.25280. Cancer. 2010. PMID: 20549824 Free article. Clinical Trial.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahé B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C. Salles G, et al. Among authors: sebban c. Blood. 2008 Dec 15;112(13):4824-31. doi: 10.1182/blood-2008-04-153189. Epub 2008 Sep 17. Blood. 2008. PMID: 18799723 Free article. Clinical Trial.
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Morschhauser F, et al. Among authors: sebban c. J Clin Oncol. 2008 Dec 20;26(36):5980-7. doi: 10.1200/JCO.2007.15.5887. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018090 Clinical Trial.
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Bachy E, et al. Among authors: sebban c. Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3. Haematologica. 2013. PMID: 23645690 Free PMC article. Clinical Trial.
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G. You B, et al. Among authors: sebban c. Cancer Chemother Pharmacol. 2015 Nov;76(5):939-48. doi: 10.1007/s00280-015-2866-9. Epub 2015 Sep 21. Cancer Chemother Pharmacol. 2015. PMID: 26391155
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Colombat P, et al. Among authors: sebban c. Ann Oncol. 2012 Sep;23(9):2380-2385. doi: 10.1093/annonc/mds177. Epub 2012 Jul 10. Ann Oncol. 2012. PMID: 22782332 Free article. Clinical Trial.
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P. Sibon D, et al. Among authors: sebban c. Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31. Haematologica. 2016. PMID: 26721893 Free PMC article. Clinical Trial.
222 results